Background
Methods
Search strategy and selection criteria
Results
Search results
Year | First Author | Prevalence | Group Type | Sample Size | Reference |
---|---|---|---|---|---|
1998 | Kakumu | 1% | General Population | 1179 | [47] |
2007 | Nguyen | 1% | General Population | 837 | [45] |
2015 | Quesada | 4.7% | General Population | 27/571 | [27] |
2015 | Do | 3.3% 1.3%*
| General population | 509 | [30] |
2003 | Tran | 2% | General population | 334 | [15] |
1996 | Corwin | 2% | General population | 188 | [49] |
2012 | Sereno | 0.38–4.3% | General population | NAb
| [21] |
2016 | Martinello | 42.5% | HIV | 89.452a
| [24] |
2015 | Nadol | 53.3% | HIV/IDU | 3010 | [32] |
2015 | Zang | 88% | HIV | 1434 | [29] |
1999 | >80% | HIV | 280 | [18] | |
2012 | Durier | 22.9% | HIV | 110 | [20] |
2016 | Nguyen | 89% | HIV | 104 | [26] |
2016 | Hser | 74% | HIV/IDU | NAb, c
| [11] |
2012 | Sereno | 95.8% | HIV/IDU | NAb
| [21] |
2012 | Gish | 87% | IDU | NAb
| [36] |
1998 | Kakumu | 47% | Liver Disease | 1179 | [47] |
2003 | Tran | 10% | Liver disease | 334 | [15] |
1996 | Corwin | 10% | Liver Disease | 188 | [49] |
2004 | Buchy | 9% | Liver disease | 45 | [46] |
2012 | Gish | 23% | Liver disease | NAb
| [36] |
1993 | Cordier | 2% | Hepatocarcinoma | 152 | [54] |
2010 | Bjoerkvoll | 12.7% | Blood donors | 1305 | [38] |
2012 | Viet | 76.4% | Blood Donors | 1200a
| [40] |
1994 | Song | 20.6% | Blood Donors | 491 | [52] |
2012 | Dunford | 26.6% | Dialysis | 8652a
| [37] |
2016 | Duong | 8% | Dialysis | 142 | [22] |
2015 | Duong | 6% | Dialysis | 113 | [31] |
2012 | Gish | 54% | Hemodialysis | NAb
| [36] |
2016 | Nadol | 28.4% | MSM | 1588 | [25] |
2012 | Dunford | 8.7% | CSW | 8652a
| [37] |
Year | Title | City | Sponsor | Status |
---|---|---|---|---|
2010–2016 | Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection | Ho Chi Minh City, Hai Phong | University of Hawaii | Active, not recruiting |
2014–2016 | The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment’s Effects on Chronic Hepatitis C Patients | Unknown | Nanogen Pharmaceutical Biotechnology Co., Ltd | Completed |
2015–2016 | Feasibility of Interventions on People Who Inject Drugs in Vietnam | |||
Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities | Ho Chi Minh City, Hanoi | Inserm-ANRS | Completed | |
2013–2016 | HCV Treatment in HIV Co-Infected Patients in Asia | Hanoi | amfAR, | Completed |
2016 | Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients | Unknown | Debiopharm International SA | Completed, has results |
2011–2016 | Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants | Unknown | Debiopharm International SA | Completed, has results |
2016–2017 | Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV | Unknown | Gilead Sciences | Recruiting |
2015 | 3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study | Novartis Pharmaceuticals | Completed | |
2014–2016 | Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities | Hanoi | National Development and Research Institutes, Inc. | Completed |